iShares US Small Cap Value Factor ETF (BATS: SVAL)

Latest news for iShares US Small Cap Value Factor ETF (BATS:SVAL)

Financial Services

Consumer Cyclical

Energy

Industrials

Basic Materials

Real Estate

Consumer Defensive

Technology

Communication Services

Utilities

Healthcare

Other

The Fund seeks to track the investment results of the Russell 2000 Focused Value Select Index (the Underlying Index), which is an objective, rules-based, equal-weighted equity index provided by FTSE Russell (the Index Provider or Russell). The Underlying Index measures the performance of small-capitalization U.S. companies with prominent value factor characteristics, as determined by the Index Provider.

Blackrock Cash Funds: Treasury, Sl Agency Shares

Atlantic Union Banksharescorp

Skywest Inc

Hibbett Sports Inc

Pfs Holding Corp.

Ardmore Shipping Corp

Teekay Tankers Ltd

Encore Wire Corp

Aris Water Solution, Inc.

Kb Home

iShares US Small Cap Value Factor ETF

Long Ideas

Media

Trading Ideas

COST

NVDA

SVAL

On CNBC’s “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management chose iShares US Small Cap Value Factor ETF (BATS: SVAL) as her pick.

CNBC&#39;s Final Trades: Nvidia, Costco Wholesale, Macy&#39;s And More

MRNA

NVAX

On CNBC&#39;s &#34;Fast Money Halftime Report,&#34; Bryn Talkington recommended a long position in iShares US Small Cap Value Factor ETF (BATS: SVAL).

&#39;Fast Money Halftime Report&#39; Picks For May 7

ANET

FTAI

On CNBC&#39;s &#34;Fast Money Halftime Report,&#34; the investment committee gave their final trades of the day.

Aureus Asset Management CEO Karen Firestone likes The Blackstone Group Inc. (NYSE: BX).

&#34;Halftime Report&#34; Final Trades: Blackstone, Arista Networks And More

Jefferies analyst Randal Konik reiterates Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Underperform and maintains $220 price target.

News

Price Target

Reiteration

Analyst Ratings

LULU

Jefferies Reiterates Underperform on Lululemon Athletica, Maintains $220 Price Target

Guidance

DXCM

DexCom Sees Q3 2024 Revenue $975M-$1.00B vs $1.15B Est.

SSNC

SS&C Technologies Revises FY24 Adjusted Revenue Forecast From ~$5.694B – $5.854B To $5.706B – $5.866B (Est $5.78B),  Adjusted EPS From $4.93 – $5.17 To $4.98 – $5.22 (Est $5.11)

Horace Mann Educators Expects FY 2024 Core EPS Between $2.40 - $2.70, With Q2 Core EPS Of $0.18- $0.20; Confidence In Achieving 10% Return On Equity By 2025 Amid Profitability Restoration And Sales Growth

Buybacks

The Hartford Board Authorizes New $3B Buyback Program

Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. This is a 34.38 percent decrease over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $1.94 billion which missed the analyst consensus estimate of $1.95 billion by 0.62 percent. This is a 2.90 percent decrease over sales of $2.00 billion the same period last year.

Earnings

Earnings Misses

Weyerhaeuser Q2 Adj $0.21, Inline, Sales $1.94B Miss $1.95B Estimate

Payable Sept. 26 To Shareholders Of Record As Of Aug. 27

Dividends

VOYA

Voya Financial Announces 12.5% Increase In Dividend From $0.40 To $0.45 Per Share For Q3 2024

Novo Nordisk A/S Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) experienced a notable decline on Thursday. This movement follows a significant announcement from <a href="https://www.benzinga.com/news/24/07/39966690/viking-therapeutics-stock-surges-as-company-advances-weight-loss-drug-to-late-stage-trial-what-inves">competitor Viking Therapeutics Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>).
What To Know: Viking Therapeutics announced the company has advanced its obesity candidate VK2735 into late-stage trials. This <a href="https://www.benzinga.com/news/24/07/39966690/viking-therapeutics-stock-surges-as-company-advances-weight-loss-drug-to-late-stage-trial-what-inves">advancement has intensified competition</a> in the GLP-1 market, which is currently led by Novo Nordisk and Eli Lilly corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
Viking Therapeutics&#8217; report of promising results for its obesity drug, showing up to a 15% reduction in body weight over 13 weeks, has pressured Novo Nordisk. This development challenges Novo Nordisk's leading position in the obesity treatment market.
What Else: The options market for Novo Nordisk has shown a predominantly bearish sentiment recently. Out of eight detected trades, 62% were bearish, including three put options totaling $155,555 and five call options amounting to $255,360.
Novo Nordisk&#8217;s trading volume reached 1,568,565, with the stock nearing oversold conditions according to RSI indicators. The company's next earnings report is expected in 13 days. 
Analyst Opinions: Cantor Fitzgerald recently downgraded Novo Nordisk to &#8216;Overweight&#8217; but maintained a price target of $160.
NVO Price Action: Novo Nordisk shares were down by 2.88% at $127.86 according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/checkout/benzinga-pro-essential-2024?utm_source=BZprocontent072524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="540" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-1024x540.png" alt="" class="wp-image-457886" style="width:425px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-1024x540.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO.png 1077w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39966014/can-independent-bank-corp-run-higher-on-rising-earnings-estimates">Can Independent Bank Corp. Run Higher on Rising Earnings Estimates?</a></li>
</ul>
Photo via Shutterstock.

Health Care

After-Hours Center

Movers

VKTX

Novo Nordisk Shares Decline Amid Competitive Pressure

SS&C Sees FY24 Revenue $5.7B-$5.86B Vs $6.03B Estimate; Sees Adj. EPS $4.98-$5.22 Vs $5.64 Estimate

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.39 by 10.26 percent. The company reported quarterly sales of $1.004 billion which missed the analyst consensus estimate of $1.036 billion by 3.13 percent. This is a 15.23 percent increase over sales of $871.300 million the same period last year.

Earnings Beats

DexCom Q2 2024 Adj EPS $0.43 Beats $0.39 Estimate, Sales $1.004B Miss $1.036B Estimate

Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) reported quarterly earnings of $3.97 per share which beat the analyst consensus estimate of $3.53 by 12.46 percent. The company reported quarterly sales of $384.55 million which beat the analyst consensus estimate of $372.57 million by 3.22 percent. This is a 30.02 percent increase over sales of $295.77 million the same period last year.

KNSL

Kinsale Cap Gr Q2 2024 Adj EPS $3.97 Beats $3.53 Estimate, Sales $384.55M Beat $372.57M Estimate

Data reviewed complies with standards that would be&nbsp;used to evaluate an EU Marketing Authorization Application
PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), a biotechnology company focused on developing and commercializing DNA medicines to&nbsp;help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that&nbsp;the European Medicines Agency's Committee for Advanced Therapies (CAT) has certified the quality and non-clinical data for INO-3107, INOVIO's lead candidate&nbsp;for&nbsp;the treatment of Recurrent Respiratory Papillomatosis (RRP). The certification confirms that INOVIO's chemistry, manufacturing and controls (CMC) data and nonclinical results available to date comply with the scientific and technical standards that would be used for evaluating a European Marketing Authorization Application.

Biotech

General

Inovio Receives Advanced Therapy Medicinal Product Certificate From EMA For Quality And Non-Clinical Data For Lead Candidate INO-3107

Universal Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULH#NASDAQ">ULH</a>) reported quarterly earnings of $1.17 per share which beat the analyst consensus estimate of $1.14 by 2.63 percent. The company reported quarterly sales of $462.164 million which beat the analyst consensus estimate of $461.600 million by 0.12 percent. This is a 12.02 percent increase over sales of $412.572 million the same period last year.

Universal Logistics Hldgs Q2 2024 GAAP EPS $1.17 Beats $1.14 Estimate, Sales $462.164M Beat $461.600M Estimate

Wolfe Research analyst Steve Fleishman downgrades NextEra Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) from Outperform to Peer Perform.

Downgrades

Wolfe Research Downgrades NextEra Energy Partners to Peer Perform

SS&C Technologies Expects Q3 Adjusted Revenue $1.42B – $1.46B (Est $1.44B), Adj EPS Of $1.21 – $1.27 (Est $1.27)

SS&C Sees Q3 2024 Adj. Revenue $1.42B-$1.46B Vs $1.432B Estimate; Sees Adj. EPS $1.21-$1.27 Vs $1.20 Estimate

Magyar Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGYR#NASDAQ">MGYR</a>) reported quarterly earnings of $0.27 per share. This is a 10 percent decrease over earnings of $0.30 per share from the same period last year.

MGYR

Magyar Bancorp Q3 EPS $0.27 Down From $0.30 YoY

Exponent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPO#NASDAQ">EXPO</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.50 by 14 percent. The company reported quarterly sales of $140.536 million which beat the analyst consensus estimate of $130.827 million by 7.42 percent. This is a 0.22 percent increase over sales of $140.221 million the same period last year.

EXPO

Exponent Q2 2024 GAAP EPS $0.57 Beats $0.50 Estimate, Sales $140.536M Beat $130.827M Estimate

Erie Indemnity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>) reported quarterly earnings of $3.13 per share which beat the analyst consensus estimate of $2.55 by 22.75 percent.

ERIE

Erie Indemnity Q2 2024 GAAP EPS $3.13 Beats $2.55 Estimate

COLM

Columbia Sportswear Sees Q4 2024 EPS $3.65-$4.05

Greenback And Yen Extend Gains

Climbing Limo GDP Forecast For Q2 2024

James Bullard On FAIT, Nominal GDP Targeting, And The Fed's Upcoming Framework Review

What Biden's Historic Election Decision Means For Markets

Hoisington Investment Management Q2 2024 Review And Outlook

Positioning For The 2024 U.S. Presidential Election

Yen's Surge Continues, While PBOC Surprises With Another Rate Cut, And U.S. 2-30 Year Yield Curve Ends Inversion

Looking Back At Equity Factors In Q2 2024 With WisdomTree

Country Risk: My 2024 Data Update

U.S. GDP Growth Beats Expectations, But Fails To Dent The Market's Faith In Rate Cuts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

iShares US Small Cap Value Factor ETF

News

Latest news for iShares US Small Cap Value Factor ETF (BATS:SVAL)

Thursday, December 30, 2021

Friday, May 07, 2021

Monday, March 08, 2021